Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will take steps to help ensure eligible people with migraines can access NICE-approved calcitonin gene-related peptide antibody medicines.

The National Institute for Health and Care Excellence (NICE) has published guidance recommending erenumab, galcanezumab and fremanezumab, all of which are calcitonin gene-related peptide antibody medicines, for preventing migraine in adults for routine funding in the National Health Service in England, subject to specified criteria. NHS England is legally required to fund medicines recommended in a NICE technology appraisal, usually within three months of final guidance. This funding requirement ensures that there is consistency of access for to NICE recommended medicines. The NHS Constitution states that patients have the right to drugs and treatments recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.